Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?
3 Motley Fool contributors share their top picks for February.
Industry Focus zooms in on restructuring, new drugs, and possible threats for pharma giant Novartis.
In this week's Industry Focus, our analysts discuss their favorites of the successful 2014 healthcare large-cap stocks.
Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?
Three Motley Fool analysts tell investors what they believe are the year's most memorable events in the healthcare sector.
Just because you own Allergan doesn't mean you should necessarily own Actavis.
Specialty and generic drugmaker Actavis plc reported another monster quarter last week. Here are five things management wants investors to know going forward.
Valeant Pharmaceuticals' takeover bid for Allergan has turned hostile in more ways than one.
Actavis posted third-quarter earnings this morning. Here's what you need to know.